Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:20 PM
Ignite Modification Date:
2025-12-24 @ 4:20 PM
NCT ID:
NCT04001166
Eligibility Criteria:
Inclusion Criteria:
* Genotyped for CYP2C9/rs1799853, CYP2C9/rs1057910 and VKORC1/rs9923231
* Diagnosed with at least one of the following:
* Atrial Fibrillation and Flutter (I48)
* Ischemic Heart Disease (I20-I25)
* Cerebrovascular disease (I63,I65,I66, 167.2, I69.3-I69.8)
* Atherosclerosis (I70)
* Pulmonary embolism (I26)
* Phlebitis and thrombophlebitis (I80)
* Portal vein thrombosis (I81)
* Other venous embolism and thrombosis (I82)
* Purchased at least one of the following drugs between January 1st 2007 - December 31st 2018:
* Anticoagulants: Warfarin, Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Heparin, Enoxaparin, Dalteparin
* Antiplatelets: Clopidogrel, Ticagrelor, Acetylsalicylic acid
Exclusion Criteria:
* Permanent residence in Finland less than 12 months during the follow-up period
* Purchase of any of the antithrombotic drugs listed above between January 1st 2005 - December 31st 2006
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04001166
Study Brief:
Protocol Section:
NCT04001166